Post A Reply
Allstocks.com's Bulletin Board
.11 and Up!
SNSS ON THE WAY UP
» Post A Reply
Post A Reply
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by m69jump: [QB] Finally, Sunesis Pharmaceuticals, Inc. (SNSS) will also be presenting at ASCO [Abstract #TPS201, “Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia”]. Unlike the aforementioned frontline trials being conducted under SPA’s, Sunesis is studying vosaroxin in relapsed/refractory AML in an ongoing Phase 3 trial. Approximately 450 patients will be randomized to receive either vosaroxin or placebo in combination with cytarabine. Cytarabine, a generic chemotherapy drug introduced several decades ago, is already a critical part of the treatment for younger patients with AML who are fit to withstand its toxicity. Unfortunately, several companies that make cytarabine have recently experienced production difficulties and others cannot make the drug fast enough to keep up with demand. This has resulted in a severe shortage of cytarabine that has reportedly affected leukemia clinical trials being run by the Cancer and Leukemia Group B [CALGB]. Accordingly, investors will be looking to Sunesis for an update on enrollment in the VALOR Phase 3 trial to determine whether or not the cytarabine shortage has been a factor. “My personal opinion on AML affecting the elderly population is that the field is in need of a total revamp whereby certain chemotherapy agents need to be combined with targeted therapies to overcome drug resistance and provide meaningful survival data,” said Daruka Mahadevan, M.D. Ph.D., Director, Phase I Program, Arizona Cancer Center. “If you can increase the survival of a 70-year old patient by ten years, that would be a real achievement. Sapacitabine is interesting as it is an oral agent, while vosaroxin in combination of cytarabine may provide short term control – but is unlikely to provide a survival benefit.” Please click here to read MD Becker Partners' legal disclaimer. Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Michael Becker picture More articles by Michael Becker » Similarities Between the First Two Active Immunotherapies in Cancer Mar 30, 2011 Ipilimumab Approval Highlights Active Immunotherapy Renaissance Mar 27, 2011 Earthquake Highlights Opportunity for Treating Radiation Sickness Mar 14, 2011 [/QB][/QUOTE]
Instant UBB Code™
What is UBB Code™?
Disable Graemlins in this post.
*** Click here to review this topic. ***
Allstocks.com Message Board Home
© 1997 - 2013 Allstocks.com. All rights reserved.